arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Repligen Corporation

RGEN Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$178.71
▼ -0.1% Today
as of Oct 22, 16:51 ET
Last 30 days +6.38% Sep 14 → Oct 22
$161.38 $170.29 $179.21 $188.12 $197.03 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$179.45
High
$185.03
Low
$176.00
Volume
$1M
Avg Vol
$996,622
Mkt Cap
$8.2B
P/E (TTM)
350.84
Beta
—
52w High
$198.87
52w Low
$100.99
Div Yield
—
Shares Out
$56M

Recent Press Releases & News last 60 days · 12 items

Oct 16 · 20:43 StockStory
Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know
Oct 13 · 11:30 PR GlobeNewswire
Repligen to Report Third Quarter 2026 Financial Results
Oct 6 · 20:22 MT Newswires
Repligen Insider Sold Shares Worth $1,036,654, According to a Recent SEC Filing
▸ Show all 12 press releases & news Free account →

RGEN earnings at a glance

Repligen Corporation (RGEN) is scheduled to report earnings on Tuesday, October 27, 2026 — in 4 days. Analysts expect earnings per share of $0.46, compared with $0.46 in the same quarter last year (+0%). The options market is pricing a move of about ±6.6% after the report, a range of roughly $166.89 to $190.53 from today's $178.71. Over its last 6 reports the stock rose the next day 3 times and fell 3, moving ±5.2% on average; after the most recent report on Jul 28, 2026 it moved +10.9%. That means options currently expect more movement than RGEN has typically delivered. RGEN beat the consensus EPS estimate in 5 of its last 6 reported quarters. Implied volatility is currently 56%. The share price of $178.71 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$101
$199
79% of range
Avg surprise (last 6)
+11.9%
Avg reaction (last 6)
+2.1%
50% positive
Latest IV / EM
56%
EM ±6.6% · $160 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.01$0.13$0.27$0.40$0.54 Actual $0.27Actual $0.35Actual $0.30Actual $0.06Actual $0.10Actual $-0.01Actual $0.39Est $0.35Actual $0.37Est $0.40Actual $0.46Est $0.42Actual $0.49Est $0.44Actual $0.48Est $0.38Actual $0.54Est $0.45 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-654,000$53M$107M$161M$214M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jul 28, 2026Jun/2026 $0.54 $0.45 +20.0% +21.6% +10.9% earnings
Tue May 5, 2026Mar/2026 $0.48 $0.38 +26.3% +23.1% +6.3% earnings
Tue Feb 24, 20268K 2026-02-24 $0.49 $0.44 +11.4% — -0.5% earnings
Tue Oct 28, 2025Sep/2025 $0.46 $0.42 +9.5% — -5.9% earnings
Tue Jul 29, 2025Jun/2025 $0.37 $0.40 -7.5% — +4.7% earnings
Tue Apr 29, 2025Mar/2025 $0.39 $0.35 +11.4% — -2.9% earnings
Mon Sep 30, 2024Sep 2024 $-0.01 — — — — financials
Sun Jun 30, 2024Jun 2024 $0.10 — — — — financials
Sun Mar 31, 2024Mar 2024 $0.06 — — — — financials
Sat Sep 30, 2023Sep 2023 $0.30 — — — — financials
Fri Jun 30, 2023Jun 2023 $0.35 — — — — financials
Fri Mar 31, 2023Mar 2023 $0.27 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Tue Oct 27, 2026Sep/2026OTHER $0.46$0.46 0.0%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$204M$194M—$189M$182M$169M—$155M
Cost of revenue$94M$86M—$88M$89M$78M—$77M
Gross profit————————
Operating income$14M$16M—$17M$14M$7M—$-8M
Net income$5M$8M—$15M$15M$6M—$-654,000
EPS (diluted)$0.09$0.15—$0.26$0.26$0.10—$-0.01

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$607M$583M$566M$749M$709M$697M$757M$784M
Inventory$187M$179M$170M$160M$156M$153M$143M$182M
Total current assets$1.20B$1.16B$1.14B$1.10B$1.06B$1.03B$1.07B$1.13B
Total assets$2.95B$2.93B$2.95B$2.92B$2.90B$2.85B$2.83B$2.83B
Long-term debt$551M$547M$542M$538M——$526M—
Total liabilities$838M$825M$844M$841M$840M$867M$857M$814M
Total equity$2.11B$2.11B$2.11B$2.08B$2.06B$1.99B$1.97B$2.02B

Implied volatility — last 90 days

40%52%63%75%87% Jun 07 — IV 62% · EM ±8.5%Jun 08 — IV 56% · EM ±7.4%Jun 09 — IV 52% · EM ±6.6%Jun 10 — IV 54% · EM ±6.4%Jun 11 — IV 47% · EM ±5.2%Jun 12 — IV 51% · EM ±5.2%Jun 15 — IV 54% · EM ±3.9%Jun 16 — IV 68% · EM ±4.0%Jun 17 — IV 76% · EM ±3.2%Jun 19 — IV 49% · EM ±10.9%Jun 22 — IV 48% · EM ±10.0%Jun 23 — IV 50% · EM ±10.2%Jun 24 — IV 52% · EM ±10.4%Jun 25 — IV 51% · EM ±9.9%Jun 26 — IV 54% · EM ±10.4%Jun 29 — IV 55% · EM ±9.7%Jun 30 — IV 61% · EM ±10.4%Jul 01 — IV 58% · EM ±9.6%Jul 02 — IV 58% · EM ±9.4%Jul 03 — IV 60% · EM ±9.4%Jul 06 — IV 64% · EM ±8.9%Jul 07 — IV 50% · EM ±6.7%Jul 08 — IV 59% · EM ±7.3%Jul 09 — IV 60% · EM ±7.1%Jul 10 — IV 53% · EM ±5.9%Jul 13 — IV 63% · EM ±5.3%Jul 14 — IV 64% · EM ±4.7%Jul 15 — IV 73% · EM ±4.3%Jul 16 — IV 87% · EM ±3.6%Jul 20 — IV 64% · EM ±15.2%Jul 21 — IV 68% · EM ±15.9%Jul 22 — IV 60% · EM ±13.7%Jul 23 — IV 59% · EM ±13.3%Jul 24 — IV 61% · EM ±13.4%Jul 27 — IV 63% · EM ±13.2%Jul 28 — IV 48% · EM ±9.9%Jul 29 — IV 52% · EM ±10.4%Jul 30 — IV 50% · EM ±9.8%Jul 31 — IV 50% · EM ±9.5%Aug 03 — IV 54% · EM ±9.6%Aug 04 — IV 49% · EM ±8.4%Aug 05 — IV 50% · EM ±8.3%Aug 06 — IV 45% · EM ±7.3%Aug 07 — IV 45% · EM ±7.1%Aug 10 — IV 47% · EM ±6.6%Aug 11 — IV 46% · EM ±6.1%Aug 12 — IV 45% · EM ±5.6%Aug 13 — IV 47% · EM ±5.5%Aug 14 — IV 43% · EM ±4.7%Aug 17 — IV 51% · EM ±4.3%Aug 18 — IV 54% · EM ±3.9%Aug 19 — IV 56% · EM ±3.3%Aug 20 — IV 68% · EM ±2.8%Aug 24 — IV 43% · EM ±9.0%Aug 25 — IV 43% · EM ±8.7%Aug 26 — IV 43% · EM ±8.5%Aug 27 — IV 44% · EM ±8.7%Aug 28 — IV 42% · EM ±8.0%Aug 31 — IV 44% · EM ±7.8%Sep 01 — IV 41% · EM ±7.0%Sep 02 — IV 43% · EM ±7.1%Sep 03 — IV 44% · EM ±7.1%Sep 04 — IV 47% · EM ±7.3%Sep 07 — IV 53% · EM ±7.3%Sep 08 — IV 51% · EM ±6.7%Sep 09 — IV 48% · EM ±6.0%Sep 10 — IV 56% · EM ±6.6%Sep 11 — IV 55% · EM ±6.1%Sep 14 — IV 63% · EM ±5.2%Sep 15 — IV 62% · EM ±4.5%Sep 16 — IV 66% · EM ±3.9%Sep 17 — IV 68% · EM ±2.8%Sep 21 — IV 55% · EM ±11.4%Sep 22 — IV 50% · EM ±10.3%Sep 23 — IV 48% · EM ±9.6%Sep 24 — IV 49% · EM ±9.7%Sep 25 — IV 49% · EM ±9.4%Sep 28 — IV 45% · EM ±8.0%Sep 29 — IV 46% · EM ±7.8%Sep 30 — IV 46% · EM ±7.6%Oct 01 — IV 44% · EM ±7.2%Oct 02 — IV 44% · EM ±6.9%Oct 06 — IV 63% · EM ±8.3%Oct 07 — IV 60% · EM ±7.6%Oct 08 — IV 56% · EM ±6.6%

Sector peers

KYMR
Kymera Therapeutics, Inc.
$9.0B $110.85-2.3%
QGEN
Qiagen N.V.
$9.2B $50.22+2.7%
IMVT
Immunovant, Inc.
$7.0B $29.10+1.8%
KRYS
Krystal Biotech, Inc.
$9.6B $320.13-1.6%
KOD
Kodiak Sciences Inc
$6.2B $85.78-7.7%
APGE
Apogee Therapeutics, Inc.
$10.2B $135.07

RGEN earnings FAQ

When is RGEN's next earnings date?

Repligen Corporation is expected to report on October 27, 2026.

What is RGEN's expected move for earnings?

Options currently price a move of about ±6.6%, or $11.82 per share either way from $178.71.

How does RGEN stock usually react to earnings?

Across the last 6 reports the average next-day move was ±5.2%, up 3 times and down 3 times.

What EPS are analysts expecting from Repligen Corporation?

The consensus estimate is $0.46 per share, versus $0.46 a year ago.

What is RGEN's implied volatility?

RGEN's at-the-money implied volatility is about 56% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in